Zevra Therapeutics reported a loss of 48 cents per share in the second quarter, missing analysts’ expectations but exceeding revenue estimates. The company’s revenue was driven by reimbursements from the French EAP for arimoclomol, royalties, and other reimbursements. Despite the earnings miss, the company remains optimistic about its future prospects, particularly after a positive vote from the FDA’s Genetic Metabolic Diseases Advisory Committee for arimoclomol.